Understanding and Overcoming the Challenges Related to Cardiovascular Trials Involving Patients with Kidney Disease.

ABSTRACT: Cardiovascular disease is a prevalent and prognostically important comorbidity among patients with kidney disease, and individuals with kidney disease make up a sizeable proportion (30%-60%) of patients with cardiovascular disease. However, several systematic reviews of cardiovascular trials have observed that patients with kidney disease, particularly those with advanced kidney disease, are often excluded from trial participation. Thus, currently available trial data for cardiovascular interventions in patients with kidney disease may be insufficient to make recommendations on the optimal approach for many therapies. The Kidney Health Initiative, a public-private partnership between the American Society of Nephrology and the US Food and Drug Administration, convened a multidisciplinary, i

SUBMITTER: Ishida JH 

PROVIDER: S-EPMC8729590 | biostudies-literature | 2021 Sep

REPOSITORIES: biostudies-literature